Literature DB >> 12091511

Delay in diagnosis of slipped upper femoral epiphysis.

S Ankarath1, A B Y Ng, P V Giannoudis, B W Scott.   

Abstract

Treatment of slipped upper femoral epiphysis (SUFE) is directed at preventing progressive slippage, minimizing deformity and avoiding avascular necrosis and chondrolysis. Delay in treatment adversely affects long-term outcomes. In a retrospective study we assessed delays between symptom onset and evaluation of the patient in an orthopaedic department. 27 patients aged 10-16 years were grouped by source of referral (general practitioner or accident and emergency department), and hips were classified as stable or unstable according to ability to bear weight. The 27 children had 37 affected hips, 31 stable and 6 unstable. In the 20 patients referred by general practitioners, mean delay from symptom onset to orthopaedic evaluation was 119 days (range 2-504); in the 7 referred from accident and emergency departments it was 95 days (1-482). In the latter group the slips were more likely to be acute and unstable. 9 (45%) of the patients in the general-practitioner group had hip radiography before referral, all correctly diagnosed though not all the examinations included the recommended frog-lateral views. Long delays between onset and diagnosis of SUFE are most likely in patients with mild symptoms, able to bear weight on the hip. Any adolescent with undiagnosed hip or knee pain that has lasted more than a week should undergo radiological investigation of the hip, with frog-lateral as well as anteroposterior views.

Entities:  

Mesh:

Year:  2002        PMID: 12091511      PMCID: PMC1279941          DOI: 10.1177/014107680209500709

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  6 in total

1.  Knee pain as the initial symptom of slipped capital femoral epiphysis: an analysis of initial presentation and treatment.

Authors:  M J Matava; C M Patton; S Luhmann; J E Gordon; P L Schoenecker
Journal:  J Pediatr Orthop       Date:  1999 Jul-Aug       Impact factor: 2.324

2.  SLIPPED CAPITAL FEMORAL EPIPHYSIS: AN END-RESULT STUDY.

Authors:  P D WILSON; B JACOBS; L SCHECTER
Journal:  J Bone Joint Surg Am       Date:  1965-09       Impact factor: 5.284

3.  ACUTE SLIPPED CAPITAL FEMORAL EPIPHYSIS: REVIEW OF THE LITERATURE AND REPORT OF TEN CASES.

Authors:  J J FAHEY; E T O'BRIEN
Journal:  J Bone Joint Surg Am       Date:  1965-09       Impact factor: 5.284

4.  The significance of early diagnosis and treatment of slipping of the capital femoral epiphysis.

Authors:  H R Cowell
Journal:  Clin Orthop Relat Res       Date:  1966 Sep-Oct       Impact factor: 4.176

5.  Acute slipped capital femoral epiphysis: the importance of physeal stability.

Authors:  R T Loder; B S Richards; P S Shapiro; L R Reznick; D D Aronson
Journal:  J Bone Joint Surg Am       Date:  1993-08       Impact factor: 5.284

6.  A 30-year experience with bone graft epiphysiodesis in the treatment of slipped capital femoral epiphysis.

Authors:  D S Weiner; S Weiner; A Melby; W A Hoyt
Journal:  J Pediatr Orthop       Date:  1984-03       Impact factor: 2.324

  6 in total
  4 in total

1.  Screw placement in slipped upper femoral epiphysis: is good the enemy of better?

Authors:  Wiqqas Jamil; Mohamad K Allami; Bobin Varghese; Mohammed Almaiyah; Peter Giannoudis
Journal:  J Child Orthop       Date:  2007-08-10       Impact factor: 1.548

2.  Delayed diagnosis of slipped upper femoral epiphysis.

Authors:  N H Harris
Journal:  J R Soc Med       Date:  2002-09       Impact factor: 18.000

Review 3.  The epidemiology and demographics of slipped capital femoral epiphysis.

Authors:  Randall T Loder; Elaine N Skopelja
Journal:  ISRN Orthop       Date:  2011-09-21

4.  Diagnosing slipped capital femoral epiphysis amongst various medical specialists.

Authors:  A Lam; S A Boenerjous; Y Lo; J M Abzug; J Kurian; M C Liszewski; D E Sanderson; J M Scholnick; B H Taragin; J A Gomez; N Y Otsuka; R Hanstein
Journal:  J Child Orthop       Date:  2018-04-01       Impact factor: 1.548

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.